Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecologic Oncology Reports 2020, 33: 100590. PMID: 32885014, PMCID: PMC7452617, DOI: 10.1016/j.gore.2020.100590.Peer-Reviewed Original ResearchNRG Oncology StudyPIK3CA hotspot mutationsHotspot mutationsOncology studiesSelective inhibitorPatientsCopanlisibPI3KCAPhase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports 2020, 31: 100532. PMID: 31934607, PMCID: PMC6951478, DOI: 10.1016/j.gore.2019.100532.Peer-Reviewed Original ResearchProgression-free survivalStable diseaseOverall survivalMixed histologyPIK3CA mutationsGrade 5 adverse eventsMedian progression-free survivalCommon grade 3Common PIK3CA mutationCTCAE version 4GOG performance statusNRG Oncology StudyMedian overall survivalObjective tumor responsePhase II trialPhase II evaluationBest overall responsePIK3CA gene mutationsPIK3CA hotspot mutationsSelective inhibitorEligible patientsMeasurable diseaseHotspot PIK3CA mutationsII trialPrimary endpoint